- Home
- AMAL vs PHVS Comparison
AMAL vs PHVS Comparison
Compare AMAL & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMAL
- PHVS
- Stock Information
- Founded
- AMAL 1923
- PHVS 2015
- Country
- AMAL United States
- PHVS Netherlands
- Employees
- AMAL N/A
- PHVS N/A
- Industry
- AMAL Commercial Banks
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- AMAL Finance
- PHVS Health Care
- Exchange
- AMAL Nasdaq
- PHVS Nasdaq
- Market Cap
- AMAL 1.0B
- PHVS 1.0B
- IPO Year
- AMAL 2018
- PHVS 2021
- Fundamental
- Price
- AMAL $33.17
- PHVS $18.54
- Analyst Decision
- AMAL Buy
- PHVS Strong Buy
- Analyst Count
- AMAL 4
- PHVS 5
- Target Price
- AMAL $37.13
- PHVS $40.60
- AVG Volume (30 Days)
- AMAL 146.4K
- PHVS 66.5K
- Earning Date
- AMAL 01-23-2025
- PHVS 11-13-2024
- Dividend Yield
- AMAL 1.45%
- PHVS N/A
- EPS Growth
- AMAL 16.43
- PHVS N/A
- EPS
- AMAL 3.39
- PHVS N/A
- Revenue
- AMAL $303,032,000.00
- PHVS N/A
- Revenue This Year
- AMAL N/A
- PHVS N/A
- Revenue Next Year
- AMAL $4.24
- PHVS N/A
- P/E Ratio
- AMAL $9.80
- PHVS N/A
- Revenue Growth
- AMAL 12.76
- PHVS N/A
- 52 Week Low
- AMAL $21.33
- PHVS $15.37
- 52 Week High
- AMAL $38.19
- PHVS $33.00
- Technical
- Relative Strength Index (RSI)
- AMAL 40.18
- PHVS 51.83
- Support Level
- AMAL $33.05
- PHVS $18.18
- Resistance Level
- AMAL $34.20
- PHVS $19.88
- Average True Range (ATR)
- AMAL 0.90
- PHVS 1.11
- MACD
- AMAL -0.13
- PHVS 0.17
- Stochastic Oscillator
- AMAL 35.47
- PHVS 76.86
About AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers a range of products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management, and trust and custody services.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.